GenLight Therapeutics, Inc. (GLTI) is developing individualized target-tailored biological and small molecule therapeutics specifically targeting disease phenotypes resistant to existing, broadly utilized in current clinical practice standard therapeutic protocols. Underlying scientific concept of the GLTI’s drug development program is based on design of drug combinations targeting individual’s disease gene expression profiles and causing transcriptional reversal of disease phenotypes.
Main focus of the GLTI’s anti-cancer drug development program is design of biological and small molecule therapeutics targeting cancer stem cell phenotypes. As an important component of individualized therapy selection and prescription assistance and advisory services, GLTI is ready to provide the services of design and maintenance of individualized models of human disease, including humanized mouse models of cancer for individual patients. These individualized patient-derived disease models will be used for evaluation of the efficiency of new therapies in real time, before selecting and administering next-in-line treatments to patients. Individualized, patient-based tumor models will be used for continuous assessment of the therapeutic utility of NEW drugs and drug combinations specifically designed against genetic targets of therapy-resistant disease phenotypes.
TARGETED COMBINATION THERAPY DIRECTED AGAINST MULTIPLE STEMNESS PATHWAY’S GENETIC DRIVERS IN CANCER STEM CELLS
Targeted combination therapy directed at multiple key genetic targets within stemness pathways in cancer stem cells is one of the most promising novel approaches for development of new and efficient treatment modalities for therapy-resistant, clinically-lethal metastatic cancers. How to deliver simultaneously the multiple targeted therapeutics having markedly distinct chemical properties and different pharmacokinetics, bioavailability, stability, and toxicity profiles? How to accomplish this coordinated delivery in vivo with clinically-sufficient precision to avoid toxicity and facilitate on-demand release in selectively targeted cancer cells? The proof of principle experiments are underway to demonstrate the feasibility of our proprietary approach to the solution of this critically important problem. Essentially all design, engineering, and lab-scale manufacturing components are in place and now it is time to put them all together into a single therapeutics assembly pipeline. Please stay tuned for follow-up updates and additional information which will be coming soon in the New Projects and Therapeutics sections of our website: http://www.genlighttechnology.com
GenLight Consulting Corporation & GenLight Diagnostics Corporation
Multiple products and services essential for practical implementation of the concept of individualized genomics-guided therapies are offered by GenLight Diagnostics, Inc. and GenLight Consulting, Inc. and would allow a prediction of the effectiveness and safety of individualized target-tailored therapy in real time. For example, to assist cancer patients we will use the proprietary individualized experimental models of the disease generated by implanting tumor cells from the patient in orthotopic organs of humanized mouse. Various therapies or combinations of therapy can be tested in these individualized models to select in real time most efficient therapeutic modalities and regimens. GenLight Consulting, Inc. is offering genetic consulting services designed to assist practicing physicians and patients. A medical doctor from GenLight Consulting will review all of the patient’s genetic data obtained from GenLight Diagnostics, Inc. or other sources with the patient and/or physician and help him or her select the best possible cancer treatment and personalized approaches to disease management.
NEW: We are offering a broad range of proprietary products and services to assist healthy people in understanding the individual's genetic risk of developing common human disorders.
We will help to measure, calculate, evaluate, and understand your individual genetic risk of developing common human disorders. If desired, we will be able to perform this analysis for all your family members, including your children and your future offspring. We will assess your individual genetic risk factors for developing the following major common human disorders:
Alzheimer’s disease (AD)
Autism Spectrum Disorders (ASD)
Bipolar disease (BD)
Rheumatoid arthritis (RA)
Coronary artery disease (CAD)
Crohn's disease (CD)
Type 1 diabetes (T1D)
Type 2 diabetes (T2D)
Ankylosing spondylitis (AS)
Graves' disease (autoimmune thyroid disease; AITD);
Multiple sclerosis (MS);
Breast cancer (BC);
Prostate cancer (PC);
Lung cancer (LC);
Ovarian cancer (OC);
Parkinson’s disease (PD);
Systemic lupus erythematosus (SLE)
Huntington’s disease (HD)
Ulcerative colitis (UC)
Multiple autoimmune diseases (MAD)
GenLight Technologies Corporation, Inc. (GLTCI)